Aleta Biotherapeutics, a privately held immuno-oncology company focused on transforming cellular therapeutics to allow a broad spectrum of cancer indications to be targeted, today announced a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, to be held in Washington, D.C. and in a virtual platform on November 10-14, 2021.
Full details of the poster presentation are listed below:
Title: Evaluation and development of dual and triple antigen targeting CAR-T Engager proteins for Her2-positive CNS metastases and solid tumors
Presenter: Paul D. Rennert, PhD
Date & Time: Available 7 a.m. EST on Friday, November 12, 2021
Poster Session: Cellular Therapies
Abstract Number: 160
About Aleta Biotherapeutics
Our mission is to create cell therapeutics that provide robust and durable clinical benefit for patients suffering from advanced hematologic cancers and refractory solid tumors. Aleta’s CAR-T Engager technology incorporates potent multi-antigen targeting, optimal T cell fitness, and persistence to aggressively attack cancers. We use this technology to build programs that solve specific clinical issues, including cell therapy relapses due to antigen loss and the challenge of overcoming solid tumor heterogeneity. Our lead development program has won landmark clinical support from Cancer Research UK and will enter Phase1/2 trials in 2022. To discover more about our mission, technologies and pipeline please visit www.aletabio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211001005525/en/
Source: Aleta Biotherapeutics
View this news release online at:
http://www.businesswire.com/news/home/20211001005525/en
